Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 2.300-2.500 for the period, compared to the consensus EPS estimate of 2.340. The company issued revenue guidance of $16.0 billion-$16.4 billion, compared to the consensus revenue estimate of $16.0 billion. Teva Pharmaceutical Industries also updated its FY24 guidance to $2.30-2.50 EPS.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on TEVA. Bank of America lifted their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a buy rating in a research report on Thursday, May 30th. StockNews.com raised Teva Pharmaceutical Industries from a buy rating to a strong-buy rating in a research report on Saturday. Barclays lifted their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an overweight rating in a research report on Thursday. Argus raised Teva Pharmaceutical Industries from a hold rating to a buy rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. Finally, Piper Sandler reaffirmed an overweight rating and set a $20.00 target price (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $18.67.
Check Out Our Latest Stock Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Price Performance
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The company had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. On average, analysts expect that Teva Pharmaceutical Industries will post 2.32 EPS for the current fiscal year.
Insider Activity at Teva Pharmaceutical Industries
In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Vikki L. Conway sold 15,219 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the sale, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The disclosure for this sale can be found here. Insiders sold 549,719 shares of company stock worth $9,353,736 in the last three months. 0.55% of the stock is owned by insiders.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Articles
- Five stocks we like better than Teva Pharmaceutical Industries
- What Are Dividend Champions? How to Invest in the Champions
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- What is the NASDAQ Stock Exchange?
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.